Pazopanib for the treatment of breast cancer. [Review]
Publication details: 2012; ISSN:- 1354-3784
- *Angiogenesis Inhibitors/tu [Therapeutic Use]
- *Breast Neoplasms/dt [Drug Therapy]
- *Protein Kinase Inhibitors/tu [Therapeutic Use]
- *Pyrimidines/tu [Therapeutic Use]
- *Sulfonamides/tu [Therapeutic Use]
- Breast Neoplasms/ge [Genetics]
- Female
- Humans
- Protein-Tyrosine Kinases/ai [Antagonists & Inhibitors]
- Tumor Markers, Biological
- Washington Cancer Institute
- Journal Article
- Research Support, N.I.H., Extramural
- Review
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
| Journal Article | MedStar Authors Catalog | Article | 22233389 | Available | 22233389 |
INTRODUCTION: Several clinical trials have shown clinical benefit of angiogenesis inhibitors in the treatment of solid tumors. Pazopanib is a multitargeted tyrosine kinase inhibitor that is currently approved for the treatment of patients with advanced renal cell carcinoma (RCC). AREAS COVERED: In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. Preclinical data show the anti-tumor activity of pazopanib in animal models. Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway. EXPERT OPINION: The development of biomarkers predictive of response and toxicity to angiogenesis inhibitors remains a challenging endeavor and is necessary to help guide treatment decision.
English